These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6810773)

  • 1. Optimal myocardial protection with fluosol cardioplegia.
    Magovern GJ; Flaherty JT; Gott VL; Bulkley BH; Gardner TJ
    Ann Thorac Surg; 1982 Sep; 34(3):249-57. PubMed ID: 6810773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of perfluorocarbon cardioplegia over blood or crystalloid cardioplegia.
    Kanter KR; Jaffin JH; Ehrlichman RJ; Flaherty JT; Gott VL; Gardner TJ
    Circulation; 1981 Aug; 64(2 Pt 2):II75-80. PubMed ID: 7249332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the hypertrophied pig myocardium. A comparison of crystalloid, blood, and Fluosol-DA cardioplegia during prolonged aortic clamping.
    Novick RJ; Stefaniszyn HJ; Michel RP; Burdon FD; Salerno TA
    J Thorac Cardiovasc Surg; 1985 Apr; 89(4):547-66. PubMed ID: 3157028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of blood cardioplegia to protect myocardium at lower temperatures.
    Magovern GJ; Flaherty JT; Gott VL; Bulkley BH; Gardner TJ
    Circulation; 1982 Aug; 66(2 Pt 2):I60-7. PubMed ID: 6805979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of controlled reperfusion after ischemia. XIX. Reperfusate composition: benefits of blood cardioplegia over fluosol DA cardioplegia during regional reperfusion--importance of including blood components in the initial reperfusate.
    Acar C; Partington MT; Buckberg GD
    J Thorac Cardiovasc Surg; 1991 Feb; 101(2):284-93. PubMed ID: 1992239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved myocardial protection with perfluorocarbon cardioplegia.
    Gardner TJ; Flaherty JT; Kanter KR; Magovern GJ
    Prog Clin Biol Res; 1983; 122():405-17. PubMed ID: 6878379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of aerobic metabolism during global ischemia with perfluorocarbon cardioplegia improves myocardial preservation.
    Flaherty JT; Jaffin JH; Magovern GJ; Kanter KR; Gardner TJ; Miceli MV; Jacobus WE
    Circulation; 1984 Mar; 69(3):585-92. PubMed ID: 6692519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of fluosol-polyethylene glycol cardioplegia on cold, preserved rabbit heart.
    Bhayana JN; Tan ZT; Bergsland J; Balu D; Singh JK; Hoover EL
    Ann Thorac Surg; 1997 Feb; 63(2):459-64. PubMed ID: 9033320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic monitoring during continuous warm- and cold-blood cardioplegia by means of myocardial tissue pH and PO2.
    Carrier M; Trudelle S; Khalil A; Pelletier LC
    Can J Surg; 1998 Apr; 41(2):142-8. PubMed ID: 9575998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluosol cardioplegia--a method of optimizing aerobic metabolism during arrest.
    Rousou JH; Dobbs WA; Engelman RM
    Circulation; 1982 Aug; 66(2 Pt 2):I55-9. PubMed ID: 7083547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluosol cardioplegia results in complete functional recovery: a comparison with blood cardioplegia.
    Pearl JM; Laks H; Drinkwater DC; Meneshian A; Martin SM; Curzan M; Chang PA
    Ann Thorac Surg; 1992 Dec; 54(6):1144-50. PubMed ID: 1449301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pluronic-free perfluorocarbon cardioplegia improves myocardial oxygenation.
    Johnson DL; Greene PS; Gott VL; Gardner TJ
    Circulation; 1988 Nov; 78(5 Pt 2):III153-7. PubMed ID: 3180395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced myocardial protection during ischemic arrest. Oxygenation of a crystalloid cardioplegic solution.
    Bodenhamer RM; DeBoer LW; Geffin GA; O'Keefe DD; Fallon JT; Aretz TH; Haas GS; Daggett WM
    J Thorac Cardiovasc Surg; 1983 May; 85(5):769-80. PubMed ID: 6843158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioplegic protection with hypothermic K-Fluosol DA and K/Mg-Fluosol DA solutions.
    Kyösola K; Harjula A; Mattila S; Aalto-Setälä K; Mattila I; Mattila P; Salmenperä M; Merikallio E
    Scand J Thorac Cardiovasc Surg; 1985; 19(3):267-72. PubMed ID: 4081676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of temperature and hematocrit level of oxygenated cardioplegic solutions on myocardial preservation.
    Rousou JA; Engelman RM; Breyer RH; Otani H; Lemeshow S; Das DK
    J Thorac Cardiovasc Surg; 1988 Apr; 95(4):625-30. PubMed ID: 3352296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of myocardial protective effects between GIK solution and St. Thomas solution by use of canine isolated heart-lung preparations].
    Ina H; Yasuda I
    Nihon Kyobu Geka Gakkai Zasshi; 1989 Nov; 37(11):2318-27. PubMed ID: 2693545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved myocardial preservation during global ischemia by continuous retrograde coronary sinus perfusion.
    Bolling SF; Flaherty JT; Bulkley BH; Gott VL; Gardner TJ
    J Thorac Cardiovasc Surg; 1983 Nov; 86(5):659-66. PubMed ID: 6632941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent.
    Bessho R; Chambers DJ
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):993-1003. PubMed ID: 11689806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between preischemic hypothermia and cardioplegic solutions in the neonatal lamb heart.
    Aoki M; Nomura F; Mayer JE
    J Thorac Cardiovasc Surg; 1994 Mar; 107(3):822-8. PubMed ID: 8127111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase C isoform-dependent myocardial protection by ischemic preconditioning and potassium cardioplegia.
    Lu K; Otani H; Yamamura T; Nakao Y; Hattori R; Ninomiya H; Osako M; Imamura H
    J Thorac Cardiovasc Surg; 2001 Jan; 121(1):137-48. PubMed ID: 11135170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.